Sentences with phrase «for vaccine responses»

One of the biggest challenges for vaccinomics is that it is extremely difficult to identify the genes responsible for vaccine responses.

Not exact matches

In some cases, the doctor will advise a blood test for your baby around two months after the vaccination to assess their body's response to a particular vaccine.

The list for your baby includes improved immunity and respiratory health associated with a 50 % SIDS reduction, fewer allergies, asthma, and ear infections, a better vaccine response, and reduction of chronic diseases like Crohn's and Diabetes.

He said that the most exciting arenas of immunology today include new strategies for vaccines and studies of regulatory T lymphocytes and the innate immune response, which is essentially the most general form of attacking pathogens.

In response to the Ebola Zaire outbreak, several of these vaccines have been fast tracked for human use.

«Understanding the host response will be a critical area in vaccine research,» says George Kemble, vice president of research and development for MedImmune Vaccines, recently purchased by AstraZeneca.

Trevor Mundel, president of global health at the Gates Foundation, talks to Scientific American editor - in - chief Mariette DiChristina about the Coalition for Epidemic Preparedness Innovations (CEPI) and the efforts to create vaccine platforms for rapid responses to epidemics.

Vaccines 2.0 Rather than take Han's broader approach, Stanford University's Mark Davis, director of the Institute for Immunity, Transplantation and Infection, is focusing on unraveling one specific piece of the puzzle: the immune response to flu vaccination.

In collaboration with many researchers (graduate students, postdocs, and faculty elsewhere), we have examined the role of cross-immunity on the evolution and dynamics of influenza; the impact of behavioral changes, long periods of infectiousness, variable infectivity, co-infections, prostitution, social networks, and vaccine efficacy on HIV dynamics; the role of exogenous re-infection, variable progression rates, vaccination, public transportation, close and casual contacts on tuberculosis dynamics and control; the impact of life - history vector dynamics on dengue epidemics; and on the identification of time - response scales for epidemics of foot and mouth disease.

Essentially, he's looking for immune cells with barcodes that proliferate in individuals with a good response, as opposed to those in whom the vaccine is ineffective.

Although previous studies of similar nanoparticles have found an effect of nanoparticle shape and size on antibody responses, such a trend was not seen at significant levels for the DENV2 - E vaccine.

It is the stuff of dreams for flu scientists, but it could be within reach if a new type of vaccine that elicits an immune response from white blood cells is combined with traditional vaccines.

A team led by Ron Dagan, a pediatric infectious disease specialist at Soroka University Medical Center in Beer - Sheva, Israel, wanted to know if a new pneumococcal vaccine based on tetanus toxoid would change infants» immune responses to the standard regimen of vaccines, including those for diphtheria, tetanus, pertussis (DTP), and Haemophilus influenzae type B, which protects against meningitis.

«These results imply that, of the options currently available utilizing adjuvants included in the national stockpile, based on the immune response data, AS03 should be considered a first - line adjuvant for strategies incorporating an inactivated H7N9 vaccine in adults,» the authors write.

Adjuvants, such as aluminum salts, have been integrated into vaccines for more than 70 years to augment the body's immune response to pathogens.

«We've shown that a specific type of these cells, known as follicular helper T (Tfh) cells are not only necessary, but are a limiting factor that differentiates between an average and a potent antibody response to HIV,» says Crotty, a scientific collaborator with the Center for HIV / AIDS Vaccine Immunology & Immunogen Discovery (CHAVI - ID), a major research consortium led by The Scripps Research Institute.

«If it does interfere with our immune response, it could become a target for vaccine development, not only for Zika virus, but possibly other viruses as well.

La Jolla Institute scientist Shane Crotty, Ph.D., a respected vaccine researcher and member of one of the nation's top AIDS vaccine consortiums, showed that certain helper T cells are important for triggering a strong antibody response against HIV, the virus that causes AIDS.

The researchers found that in mice, a single injection of 30 millionths of a gram of these mRNAs — a small fraction of the dose used for a typical vaccine — induced a rapid immune response, which protected mice from intravenous exposure to a separate Zika strain two weeks later.

This finding helps explain why immune responses to dengue are highly variable, and it has complex implications for epidemiology, disease, and vaccine deployment.

«An RSV vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier laboratory studies,» says study leader Ruth A. Karron, MD, director of the Center for Immunization Research and a professor in the Department of International Health at the Bloomberg School.

«The idea behind this study was to re-evaluate the bar that was previously established for evaluating a person's immune response to influenza vaccines,» said the study's principal investigator Matthew J. Memoli, M.D., director of the Clinical Studies Unit in NIAID's Laboratory of Infectious Diseases.

«Approved vaccines for many diseases work by inducing antibody responses.

Group C was composed of women with counts below 200, the defining level of AIDS for which response to an HPV vaccine had not yet been studied.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

But in truth, most (26 of 28 vaccines currently licensed for human use) stimulate primarily a B - cell or antibody response, which in many cases is sufficient.

And though it's not a substitute for vaccines, hand washing is critical in preventing and controlling infectious disease, writes Joel C. Gaydos of the Defense Department's Global Emerging Infections Surveillance and Response System in a commentary accompanying the report.

The CDC schedule for childhood vaccinations, which relies on recommendations from the Advisory Committee on Immunization Practices and is endorsed by the AAP, is drawn up based on data detailing when the body's immune system will mount the best response to the vaccine and, second, balanced against the need to protect kids at the earliest age possible.

With the completion of the first phase of the Human Genome Project in 2000, and the advent of sequencing technologies that can detect gene variations such as single nucleotide polymorphisms (SNPs), for the first time scientists have the tools in hand to find the key immune genes and genetic networks that play roles in vaccine response.

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.

The vaccine generated a pool of TH1 CD4 + T cells (also called helper T cells) that are necessary for an effective antibody response as well as a stable pool of CD8 + T memory cells.

Directing a vaccine and the body's immune response towards the stalk is a seemingly logical strategy for creating a shot that would provide broad protection.

«Immune responses provide clues for HIV vaccine development.»

Recent research has yielded new information about immune responses associated with — and potentially responsible for — protection from HIV infection, providing leads for new strategies to develop an HIV vaccine.

For now, whether a wild or vaccine - derived virus causes an outbreak, the response is the same: Hit the area hard and fast with massive immunization rounds and quash it within 4 months.

«The development of DNA - based vaccines with cytokine adjuvants has emerged as particularly promising for inducing antiviral and anti-tumor, cell - mediated immune responses.»

No data are yet available for trials in children, who typically have much less robust immune responses to the seasonal influenza vaccine and require a second dose.

ONLY half of women diagnosed with ovarian cancer live for five or more further years, but a «vaccine» that provokes an immune response against cancer might change that.

This is why it is so difficult for humans to mount an effective immune response and why it is challenging for researchers to develop vaccines targeting the HIV envelope proteins,» Dr. Blanchard says.

For this, a vaccine response more rapid than the spread of the virus and one that can stop damage to the cells is sufficient.

«We hope to use these findings to make the immune response to vaccines and infections faster and more productive, and slower and less active for autoimmune conditions where the body attacks itself,» Professor Vinuesa said.

«This publication is the first demonstration of the durability of the antibody responses induced by V920 out to 2 years,» the company said in a statement, using its developmental name for the vaccine.

The work, directed by researchers at St. Jude Children's Research Hospital in Memphis, Tenn., found that some study participants who reported receiving flu vaccines had a strong immune response not only against the seasonal H3N2 flu strain from 2010, when blood samples were collected for analysis, but also against flu subtypes never included in any vaccine formulation.

The degree of splitting could influence how the vaccine triggers an immune response, said one influenza vaccine expert who asked for anonymity.

For 30 years, researchers have struggled to determine which immune responses best foil HIV, information that has guided the design of AIDS vaccines and other prevention approaches.

But as President Barack Obama calls for an aggressive ramp up of the U.S. government's response, resolve is colliding with a grim reality: The epidemic is outpacing the speed with which drugs and vaccines can be produced.

However, scientists believe for practical use, these potential vaccines would require multiple doses or the addition of adjuvants, which enhance the immune response.

For the vaccine, however, a carrier is required that triggers an immune response itself.

Although an autologous tier 2 NAb response is not sufficient for vaccine protection against HIV - 1, it may be a necessary step in various strategies intended to induce bNAbs.

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV - infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.